Stress Granules Modulate SYK to Cause Microglial Cell Dysfunction in Alzheimer's Disease

Soumitra Ghosh1, Robert L Geahlen1

  • 1Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA.

Ebiomedicine
|February 13, 2016
PubMed

Insights

Stress causes microglial cells to form stress granules (SGs) that trap SYK, impairing Alzheimer's disease plaque removal. Restoring microglial phagocytosis offers therapeutic potential.

Area of Science:

  • Neuroscience
  • Immunology
  • Cell Biology

Background:

  • Microglial cells in Alzheimer's disease (AD) are recruited to amyloid-beta (Aβ) plaques but fail to clear them via phagocytosis.
  • Stressors like Aβ peptides or fibrils can compromise microglial function.

Purpose of the Study:

  • To investigate the mechanism by which stress impairs microglial phagocytosis in Alzheimer's disease.
  • To identify molecular players involved in stress-induced microglial dysfunction.

Main Methods:

  • Exposure of microglial cells to stressors (sodium arsenite, Aβ peptides/fibrils).
  • Analysis of stress granule (SG) formation and recruitment of tyrosine kinase SYK.
  • Assessment of reactive oxygen and nitrogen species production.
  • Measurement of phagocytic activity against E. coli and Aβ fibrils.
  • Examination of microglial cells from Alzheimer's disease patients and aged mice.

Main Results:

  • Stressed microglia form SGs that sequester active SYK, enhancing SG formation.
  • SYK within SGs promotes toxic reactive species production and inhibits phagocytosis of Aβ and bacteria.
  • Aged microglia are more prone to SG formation.
  • SGs containing SYK and phosphotyrosine are abundant in severe Alzheimer's disease brains.
  • Intravenous IgG treatment restores phagocytic capacity in stressed microglia.

Conclusions:

  • Stress, including Aβ exposure, leads to SG formation in microglia, sequestering SYK and impairing phagocytosis.
  • This mechanism contributes to microglial dysfunction in Alzheimer's disease.
  • Restoring microglial phagocytic activity, potentially via mechanisms like IVIg therapy, is a promising therapeutic avenue.